Výsledky vyhledávání - Judit Demeter

  • Zobrazuji výsledky 1 - 18 z 18
Upřesnit hledání
  1. 1
    Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival

    Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival Autor Ádám Nagy, Ágnes Ősz, Jan Budczies, Szilvia Krizsán, Gergely Szombath, Judit Demeter, Csaba Bödör, Balázs Győrffy

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Genotype–phenotype correlation in MYH9‐related thrombocytopenia

    Genotype–phenotype correlation in MYH9‐related thrombocytopenia Autor Fan Dong, Sufeng Li, Núria Pujol‐Moix, Naomi L.C. Luban, Sang Won Shin, Jae Hong Seo, Arlette Ruiz‐Sàez, Judit Demeter, Scott Langdon, Michael J. Kelley

    Vydáno 2005
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Regression of Ocular Adnexal Lymphoma After<i>Chlamydia Psittaci</i>–Eradicating Antibiotic Therapy

    Regression of Ocular Adnexal Lymphoma After<i>Chlamydia Psittaci</i>–Eradicating Antibiotic Therapy Autor Andrés J.M. Ferreri, Maurilio Ponzoni, Massimo Guidoboni, Carlo de Conciliis, Antonio Giordano Resti, Benedetta Mazzi, Antonia Anna Lettini, Judit Demeter, Stefania Dell’Oro, Claudio Doglioni, Eugenio Villa, Mauro Boiocchi, Riccardo Dolcetti

    Vydáno 2005
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Bacteria-Eradicating Therapy With Doxycycline in Ocular Adnexal MALT Lymphoma: A Multicenter Prospective Trial

    Bacteria-Eradicating Therapy With Doxycycline in Ocular Adnexal MALT Lymphoma: A Multicenter Prospective Trial Autor Andrés J.M. Ferreri, Maurilio Ponzoni, Massimo Guidoboni, Antonio Giordano Resti, Letterio S. Politi, Sergio Cortelazzo, Judit Demeter, Francesco Zallio, Angelo Palmas, Giuliana Muti, Giuseppina Dognini, Elisa Pasini, Antonia Anna Lettini, Federico Sacchetti, Carlo de Conciliis, Claudio Doglioni, Riccardo Dolcetti

    Vydáno 2006
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

    Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma Autor Pier Luigi Zinzani, Armando Santoro, Luigina Mollica, Sirpa Leppä, George Follows, Georg Lenz, Won Seog Kim, Arnon Nagler, Panayiotis Panayiotidis, Judit Demeter, Franck Morschhauser, Liana Rodrigues, John A. Reeves, Florian Hiemeyer, Ashok Miriyala, J. Garcia‐Vargas, Barrett H. Childs, Martin Dreyling

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    The addition of rituximab to anthracycline‐based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B‐cell lymphoma

    The addition of rituximab to anthracycline‐based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B‐cell lymphoma Autor Andrés J.M. Ferreri, Giuseppina Dognini, Osnat Bairey, Árpád Szomor, Carlos Montalbán, Barbara Horváth, Judit Demeter, Lilj Uziel, Riccardo Soffietti, John F. Seymour, Achille Ambrosetti, Rein Willemze, Maurizio Martelli, Giuseppe Rossi, Anna Candoni, Amalia De Renzo, Claudio Doglioni, Emanuele Zucca, Franco Cavalli, Maurilio Ponzoni

    Vydáno 2008
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study

    Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study Autor Mariano Provencio, Armando Santoro, Luigina Mollica, Sirpa Leppä, George Follows, Georg Lenz, W. S. Kim, Arnon Nagler, P. Panayiotidis, Judit Demeter, M. Özcan, Marina Kosinova, Krimo Bouabdallah, Franck Morschhauser, Tatiane Cristine Ishida, Liping Huang, J. Garcia‐Vargas, Barrett H. Childs, Pier Luigi Zinzani, Martin Dreyling

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

    Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial Autor Ruben A. Mesa, Alessandro M. Vannucchi, Adam J. Mead, Miklós Egyed, Anita Szőke, Aleksandr Suvorov, János Jakucs, Andrew C. Perkins, Ritam Prasad, Jiřı́ Mayer, Judit Demeter, Peter Ganly, Jack W. Singer, Huafeng Zhou, James P. Dean, Peter A. te Boekhorst, Jyoti Nangalia, Jean‐Jacques Kiladjian, Claire Harrison

    Vydáno 2017
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

    Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study Autor Martin Dreyling, Armando Santoro, Luigina Mollica, Sirpa Leppä, George Follows, Georg Lenz, Won Seog Kim, Arnon Nagler, Maria Dimou, Judit Demeter, Muhi̇t Özcan, Marina Kosinova, Krimo Bouabdallah, Franck Morschhauser, Don A. Stevens, David R. Trevarthen, Javier Muñoz, Liana Rodrigues, Florian Hiemeyer, Ashok Miriyala, J. Garcia‐Vargas, Barrett H. Childs, Pier Luigi Zinzani

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1

    Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1 Autor Martin Dreyling, Armando Santoro, Luigina Mollica, Sirpa Leppä, George Follows, Georg Lenz, W. S. Kim, Arnon Nagler, Panayiotis Panayiotidis, Judit Demeter, Muhi̇t Özcan, Marina Kosinova, Mariano Provencio, Massimo Magagnoli, Krimo Bouabdallah, Dae Seog Heo, Colin Phipps Diong, Javier Muñoz, A. Cao, Florian Hiemeyer, Florence Odongo, J. Garcia‐Vargas, Barrett H. Childs, Pier Luigi Zinzani

    Vydáno 2023
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

    Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax Autor Lili Kotmayer, Tamás László, Gábor Mikala, Richárd Kiss, Luca Lévay, Lajos Hegyi, Stefánia Gróf, Tibor Nagy, Gábor Barna, Péter Farkas, Júlia Weisinger, Zsolt Nagy, Alexandra Balogh, Tamás Masszi, Judit Demeter, Adrienn Sulák, Zoltán Kohl, Hussain Alizadeh, Miklós Egyed, Piroska Pettendi, Lajos Gergely, Márk Plander, Zsolt Pauker, András Masszi, András Matolcsy, Róbert Szász, Csaba Bödör, Donát Alpár

    Vydáno 2023
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

    Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy Autor Amer M. Zeidan, Pierre Fenaux, Marco Gobbi, Jiřı́ Mayer, Gail J. Roboz, Jürgen Krauter, Tadeusz Robak, Hagop M. Kantarjian, Jan Novák, W Wiktor-Jędrzejczak, Xavier Thomas, Mario Ojeda‐Uribe, Yasushi Miyazaki, Yoo Hong Min, Su‐Peng Yeh, Joseph Brandwein, Liana Gercheva, Judit Demeter, Elizabeth A. Griffiths, Karen Yee, Jean–Pierre J. Issa, Jan Philipp Bewersdorf, Harold Keer, Yong Hao, Mohammad Azab, Hartmut Döhner

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

    Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Autor Owen A. O’Connor, Muhi̇t Özcan, Eric D. Jacobsen, Josep M. Roncero, Judith Trotman, Judit Demeter, Tamás Masszi, Juliana Pereira, Radhakrishnan Ramchandren, Anne Beaven, Dolores Caballero, Steven M. Horwitz, Anne Lennard, Mehmet Turgut, Nelson Hamerschlak, Francesco d’Amore, Francine M. Foss, Won-Seog Kim, John P. Leonard, Pier Luigi Zinzani, Carlos Chiattone, Eric D. Hsi, Lorenz Trümper, Hua Liu, Emily Sheldon‐Waniga, Claudio Dansky Ullmann, Karthik Venkatakrishnan, E. Jane Leonard, Andrei R. Shustov

    Vydáno 2019
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

    Hairy cell leukemia and COVID-19 adaptation of treatment guidelines Autor Michael R. Grever, Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly, Timothy G. Call, Matt Cross, Claire Dearden, Judit Demeter, Sasha Dietrich, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B. Johnston, Gunnar Juliusson, Eric H. Kraut, Robert J. Kreitman, Francesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae H. Park, Aaron Polliack, Farhad Ravandi, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Enrico Tiacci, Xavier Troussard, Clive S. Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann

    Vydáno 2021
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

    Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia Autor Michael R. Grever, Omar Abdel‐Wahab, Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos, James S. Blachly, Timothy G. Call, Daniel Catovsky, Claire Dearden, Judit Demeter, Monica Else, Francesco Forconi, Alessandro Gozzetti, Anthony D. Ho, James B. Johnston, Jeffrey A. Jones, Gunnar Juliusson, Eric H. Kraut, Robert J. Kreitman, Loree Larratt, Francesco Lauria, Gerard Lozanski, Emili Montserrat, Sameer A. Parikh, Jae H. Park, Aaron Polliack, Graeme Quest, R. Kanti, Farhad Ravandi, Tadeusz Robak, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Enrico Tiacci, Xavier Troussard, Clive S. Zent, Thorsten Zenz, Pier Luigi Zinzani, Brunangelo Falini

    Vydáno 2016
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

    Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in tra... Autor Tadeusz Robak, Jie Jin, Halyna Pylypenko, Gregor Verhoef, Noppadol Siritanaratkul, Johannes Drach, Markus Raderer, Jiřı́ Mayer, Juliana Pereira, Gayane Tumyan, Rumiko Okamoto, Susumu Nakahara, Peter Hu, Carlos Appiani, Sepideh Nemat, Franco Cavalli, Achiel Van Hoof, Adriana Sheliga, Adriana Teixeira, Akihiro Tomita, Albert Oriol Rocafiguera, А. Н. Суворов, Alexy Kuzmin, Ali Khojasteh, Amel Mézlini, А К Голенков, André Bosly, Andrew R. Belch, Ann Van de Velde, Arpád Illés, Ashis Mukhopadhyay, Balkis Meddeb, Bernard De Prijck, Bernardo Garichochea, Bülent Ündar, Caballero Gabarrón, Carmen Cao, Cármino Antônio De Souza, Charles M. Farber, Cheol Won Suh, C Burcoveanu, C. Cebotaru, Cristina-Ligia Truica, Dai Maruyama, David Belada, Dina Ben Yehuda, Dmitry Udovitsa, Dolores, Enrica Morra, E. Späth‐Schwalbe, Eva González‐Barca, Evgenii A. Osmanov, Francisco Capote, Fritz Offner, Gálvez Cárdenas, Georg Heß, Georgii Manikhas, Govind Babu, Grigoriy Rekhtman, Guiseppe Rossi, Herlander Marques, Horia Bumbea, Huaqing Wang, Huiqiang Huang, Ilseung Choi, Irina Bulavina, Irina B. Lysenko, Irit Avivi, Iryna Kryachok, Jan Maciej Zaucha, Jan Novák, José Ángel Rodríguez Diaz, Judit Demeter, Julia Alexeeva, Jun Zhu, Kateryna Vilchevskaya, Kenichi Ishizawa, Kenny Mauricio, Kensei Tobinai, Kiyoshi Ando, Kudrat Abdulkadryrov, Lee‐Yung Shih, Lyudmila Kuzina, Mahmut Gümüş, Maike de Wit, Marcelo Capra, Margarida Marques, Marina Golubeva, Mario Ojeda‐Uribe, Maryna Kyselyova, Masafumi Taniwaki, Massimo Federico, Michael Crump, Michele Baccarani, Michinori Ogura, Miklós Egyed, M. Udvardy, Mitsutoshi Kurosawa, Naokuni Uike, Nuriet K. Khuageva

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

    Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial Autor Judith Trotman, Sally F. Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter Fingerle‐Rowson, Jiawen Zhu, Tina Nielsen, Deniz Şahin, Wolfgang Hiddemann, Robert Marcus, Andrew Davies, Mark Hertzberg, Andrew Grigg, Paul Cannell, Hang Quach, Stephen Opat, Constantine S. Tam, Paula Marlton, Ann Janssens, Fritz Offner, Koen Van Eygen, Randeep Sangha, Pam McKay, Jonathan Wilson, Richard van der Jagt, Daryl Roitman, Marek Trněný, Jiřı́ Mayer, Katell Le Dû, Philippe Solal‐Céligny, Guillaume Cartron, Charles Foussard, Norbert Frickhofen, Peter Schmidt, Ullrich Graeven, Tobias Gaska, Rudolf Schlag, Martin Sökler, Gabriele Prange‐Krex, Axel Florschütz, Hans‐Walter Lindemann, Christoph Schimmelpfennig, Solveig Tonndorf, Mathias Hänel, Georg Heß, Enrico Schalk, Heiko Hütten, Gottfried Doelken, Michael Pfreundschuh, Ulrich Keller, Michael Herold, Roswitha Forstpointner, Ursula Vehling‐Kaiser, Martin Hoffmann, Zita Borbényi, M. Udvardy, Judit Demeter, Alessandro Rambaldi, Enrica Morra, Federico Massimo, Ignazio Majolino, Monica Balzarotti, Gianpietro Semenzato, Miguel Canales, Francisco Javier Peñalver Párraga, Alfonso Soler Campos, Juan‐Manuel Sancho, José Antonio Márquez Navarro, Carlos Grande García, Herman Nilsson‐Ehle, Helen O. McCarthy, Chris Pocock, Shalal Sadullah, Ram Malladi, John Radford, Ed Kanfer, Anton Kruger, Dominic Culligan, Martin J.S. Dyer, Ruth Pettengell, John Seymour, John G. Gribben, Saad Al‐Ismail, F. N. Al‐Refaie, Norbert Blesing, Christopher Macnamara, Ann O’Callaghan, Andrew Haynes, George Follows, Roderick J. Johnson, David Cunningham, Kristian M. Bowles, Graham P. Collins, Eve Gallop‐Evans, Stephen Robinson, Chezhian Subash

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Autor Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, Tim Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo‐Domènech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su‐Peng Yeh, Andrei R. Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan P. Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: